FutureChem Co.Ltd (220100) - Total Liabilities

Latest as of March 2026: ₩16.93 Billion KRW ≈ $11.47 Million USD

Based on the latest financial reports, FutureChem Co.Ltd (220100) has total liabilities worth ₩16.93 Billion KRW (≈ $11.47 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore long-term investment intensity of FutureChem Co.Ltd to see how much of total assets are deployed in long-term investments.

FutureChem Co.Ltd - Total Liabilities Trend (2016–2025)

This chart illustrates how FutureChem Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 220100 total assets.

FutureChem Co.Ltd Competitors by Total Liabilities

The table below lists competitors of FutureChem Co.Ltd ranked by their total liabilities.

Company Country Total Liabilities
CFSB Bancorp Inc
NASDAQ:CFSB
USA $290.87 Million
Fidelix Co. Ltd
KQ:032580
Korea ₩11.13 Billion
Me2on Co. Ltd
KQ:201490
Korea ₩25.86 Billion
Multicampus Corporation
KQ:067280
Korea ₩83.88 Billion
Syntec Construction Public Company Limited
BK:SYNTEC
Thailand ฿3.98 Billion
ASolid Technology Co Ltd
TWO:6485
Taiwan NT$307.30 Million
Marvipol S.A.
WAR:MVP
Poland zł799.81 Million
GIIB Holdings Bhd
KLSE:7192
Malaysia RM67.48 Million

Liability Composition Analysis (2016–2025)

This chart breaks down FutureChem Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See FutureChem Co.Ltd (220100) net asset quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.54 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.32 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.24 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how FutureChem Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for FutureChem Co.Ltd (2016–2025)

The table below shows the annual total liabilities of FutureChem Co.Ltd from 2016 to 2025.

Year Total Liabilities Change
2025-12-31 ₩19.70 Billion
≈ $13.35 Million
-1.71%
2024-12-31 ₩20.04 Billion
≈ $13.58 Million
+124.71%
2023-12-31 ₩8.92 Billion
≈ $6.04 Million
-52.00%
2022-12-31 ₩18.58 Billion
≈ $12.59 Million
-23.91%
2021-12-31 ₩24.42 Billion
≈ $16.55 Million
-37.52%
2020-12-31 ₩39.08 Billion
≈ $26.49 Million
-24.91%
2019-12-31 ₩52.05 Billion
≈ $35.27 Million
+9.37%
2018-12-31 ₩47.59 Billion
≈ $32.25 Million
+440.85%
2017-12-31 ₩8.80 Billion
≈ $5.96 Million
+458.64%
2016-12-31 ₩1.58 Billion
≈ $1.07 Million
--

About FutureChem Co.Ltd

KQ:220100 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$93.15 Million
₩137.45 Billion KRW
Market Cap Rank
#19546 Global
#999 in Korea
Share Price
₩6130.00
Change (1 day)
-2.70%
52-Week Range
₩6130.00 - ₩34200.00
All Time High
₩34200.00
About

FutureChem Co.,Ltd engages in the research and development, production, and sale of chemicals, pharmaceuticals, and medical devices in South Korea and internationally. The company offers radioactive pharmaceuticals, including [18F]FDG for the treatment of general cancer diagnosis, PDvue for Parkinson's disease, Alzavue for Alzheimer's disease, and FLT for the lung cancer diagnosis. Its products i… Read more